Nanomerics

  • Developing polymer-based nanoparticles for enhanced bioavailability of oral-based drugs and targeted gene delivery for cancer indications
  • Delayed spinning out in 2006 due to large grant from Wellcome Trust in 2007; officially spun out in 2010
  • Lead product under development is neuropeptide for cancer p...
  • This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

    Related Research

    Pear Therapeutics CEO claims Novartis trial of schizophrenia therapeutic was flawed; tensions grow between digital therapeutics and pharma

    News Commentary | April 16, 2021

    The CEO of Pear Therapeutics is claiming that trial irregularities are causing misleading results regarding the schizophrenia product rolled out last year. While the results of this study are unlikely to change anything for Pear Therapeutics directly, the claimed lack of rigor in the trial speaks to... Not part of subscription

    Genevant enters partnership with Takeda for developing rare liver disease therapies

    News Commentary | September 08, 2021

    Genevant Sciences develops lipid nanoparticle (LNP) nucleic acid delivery techniques, which can be utilized for mRNA‑based applications including vaccines, protein production, and nonviral gene therapies. The two companies reached an agreement for Genevant to develop therapeutics for two undisclosed... Not part of subscription

    Regulus Therapeutics

    Company Profile | December 01, 2021

    Regulus Therapeutics was created as a joint venture between Alnylam Pharmaceuticals, an RNAi therapeutics company, and Isis Pharmaceuticals (now known as Ionis Pharmaceuticals), a company focused on anti‑sense technologies and therapeutics, in 2007 Regulus Therapeutics is focused on the ... Not part of subscription